Contract 75A50325F80036
Genentech USA, Inc · Department Of Health And Human Services · September 26, 2025
Genentech USA, Inc was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on September 26, 2025 for $37.48 million of work in pharmaceutical preparation manufacturing. Performance is in South San Francisco, CA. This is a task or delivery order issued under parent IDIQ 36F79723D0219. The contract has been modified 1 time since the base award It uses firm fixed-price contract pricing. The most recent modification was on March 17, 2026. If all options are exercised, the contract could reach $74.97 million.
Contract details
- PIID
- 75A50325F80036
- Parent IDIQ
- 36F79723D0219
- Award type
- Delivery Order
- Pricing
- Firm Fixed Price
- Competition
- Full And Open Competition
- NAICS
- 325412 · Pharmaceutical Preparation Manufacturing
- Product / service
- Drugs And Biologicals
- Place of performance
- South San Francisco, CA
- First action
- September 26, 2025
- Latest action
- March 17, 2026
Description
PROCUREMENT OF XOFLUZA (BALOXAVIR MARBOXIL) 40MG AND 80MG TABLETS
Modification timeline
-
March 17, 2026Mod P00001 · Other Administrative Action$37.48M
-
September 26, 2025Base awardPROCURENT OF XOFLUZA (BALOXAVIR MARBOXIL) 40MG AND 80MG TABLETS$37.48M
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Four Points Technology, L.L.C. | Department Of Health And Human Services | March 31, 2026 | $246.6K |
| Astrazeneca Pharmaceuticals Lp | Department Of Health And Human Services | March 31, 2026 | $122.8K |
| Ase Direct, Inc. | Department Of Health And Human Services | March 30, 2026 | $49.0K |
| Mckesson Corporation | Department Of Health And Human Services | March 30, 2026 | $9.00M |
| Emergent Biosolutions Canada Inc | Department Of Health And Human Services | March 30, 2026 | $256.40M |
| Merck Sharp & Dohme Llc | Department Of Health And Human Services | March 27, 2026 | $361.34M |
Top contractors in NAICS 325412
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Mckesson Corporation | 1,187 | $4.96B |
| 2 | Merck Sharp & Dohme Llc | 26 | $894.71M |
| 3 | Sanofi Vaccines Us Inc. | 57 | $702.38M |
| 4 | Pfizer Inc | 169 | $541.15M |
| 5 | Glaxosmithkline, Llc | 14 | $505.04M |
| 6 | Phlow Corp. | 1 | $105.27M |
| 7 | Exelan Pharmaceuticals Inc | 76 | $104.30M |
| 8 | Seqirus USA Inc | 47 | $59.15M |
| 9 | Emergent Biosolutions Canada Inc | 2 | $53.73M |
| 10 | Mckesson Specialty Distribution Llc | 1 | $51.05M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 75A50325F80036?
Contract 75A50325F80036 is a federal contract awarded to Genentech USA, Inc by Department Of Health And Human Services on September 26, 2025 for $37.48 million of work classified under PHARMACEUTICAL PREPARATION MANUFACTURING. It has been modified 1 time since the base award.
Who won contract 75A50325F80036?
Genentech USA, Inc won contract 75A50325F80036 from Department Of Health And Human Services.
How much is contract 75A50325F80036 worth?
Contract 75A50325F80036 has obligated $37.48 million to date, with a total potential value of $74.97 million if all options are exercised.